At Amunix, we have developed a novel half-life extension technology based on XTEN, a hydrophilic, unstructured polypeptide which can be recombinantly fused or chemically conjugated to other peptides, proteins, and small molecules. We have applied our XTEN technology platform to targets in a wide range of therapeutic areas, creating new protein pharmaceuticals characterized by improved efficacy, safety, and dosing.

Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in “Bioconjugate Chemistry” 

July 23, 2014 – Amunix Operating Inc. said its research paper, “Multivalent Antiviral XTEN−Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility” is now available online and will be published in an upcoming issue of “Bioconjugate Chemistry.” [read more]

Amunix Congratulates Versartis on its Positive Phase 2a Results with VRS-317

June 30, 2014 – Amunix Operating Inc., a biotechnology company developing a half-life extension technology for peptides, proteins and small molecules, congratulates Versartis, Inc. (NASDAQ:VSAR) on its positive clinical data with VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH). [read more]

Biogen Idec Signs License Agreement with Amunix for XTENylated Factor VIII

April 21, 2014 – Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties.  [read more]